Plaque Psoriasis: Usability of the Risankizumab Autoinjector Combination Product in Adults With Moderate to Severe Psoriasis
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 03 Sep 2020 Status changed from active, no longer recruiting to completed.
- 19 May 2020 Planned End Date changed from 5 Jul 2020 to 25 Aug 2020.
- 22 Oct 2019 Status changed from recruiting to active, no longer recruiting.